340 related articles for article (PubMed ID: 14760896)
1. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
Hammond E; McKinnon E; Nolan D
Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
Pace CS; Martin AM; Hammond EL; Mamotte CD; Nolan DA; Mallal SA
Antivir Ther; 2003 Aug; 8(4):323-31. PubMed ID: 14518702
[TBL] [Abstract][Full Text] [Related]
5. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
6. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals.
Gerschenson M; Shiramizu B; LiButti DE; Shikuma CM
Antivir Ther; 2005; 10 Suppl 2():M83-9. PubMed ID: 16152709
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition.
Casula M; van der Valk M; Wit FW; Nievaard MA; Reiss P
HIV Med; 2007 Jan; 8(1):32-7. PubMed ID: 17305930
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
Nolan D; Hammond E; Martin A; Taylor L; Herrmann S; McKinnon E; Metcalf C; Latham B; Mallal S
AIDS; 2003 Jun; 17(9):1329-38. PubMed ID: 12799554
[TBL] [Abstract][Full Text] [Related]
10. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
[TBL] [Abstract][Full Text] [Related]
11. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
Mallal SA; John M; Moore CB; James IR; McKinnon EJ
AIDS; 2000 Jul; 14(10):1309-16. PubMed ID: 10930144
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.
Rabing Christensen E; Stegger M; Jensen-Fangel S; Laursen AL; Ostergaard L
Clin Infect Dis; 2004 Nov; 39(9):1371-9. PubMed ID: 15494915
[TBL] [Abstract][Full Text] [Related]
13. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
Maagaard A; Holberg-Petersen M; Kvittingen EA; Sandvik L; Bruun JN
HIV Med; 2006 Jan; 7(1):53-8. PubMed ID: 16313293
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.
Maagaard A; Holberg-Petersen M; Kollberg G; Oldfors A; Sandvik L; Bruun JN
Antivir Ther; 2006; 11(5):601-8. PubMed ID: 16964828
[TBL] [Abstract][Full Text] [Related]
15. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy.
Haugaard SB; Andersen O; Pedersen SB; Dela F; Richelsen B; Nielsen JO; Madsbad S; Iversen J
J Med Virol; 2005 Sep; 77(1):29-38. PubMed ID: 16032748
[TBL] [Abstract][Full Text] [Related]
16. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
Nolan D; John M; Mallal S
Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
[TBL] [Abstract][Full Text] [Related]
18. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
19. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
[TBL] [Abstract][Full Text] [Related]
20. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
